MyFinsight
Home
Blog
About
Relay Therapeutics, Inc. (RLAY)
Relay Therapeutics, Inc. (RLAY)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$54,109K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Proceeds from maturities and sal...
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Purchases of investments
Net loss
Prepaid expenses and other curre...
Net amortization of premiums and...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-83,707
-73,291
-54,890
-74,149
Depreciation expense
360
504
599
748
Stock compensation expense
9,179
10,537
13,067
15,527
Impairment of intangible asset
0
-
0
0
Loss on disposal of property and equipment
0
-
-35
-353
Net amortization of premiums and discounts on investments
624
782
857
1,101
Prepaid expenses and other current assets
751
-7,364
-3,822
3,966
Operating lease assets and liabilities, net
-507
-506
-508
-507
Accounts payable and accrued expenses
20,522
3,666
-6,534
-507
Deferred revenue
0
-
0
0
Other liabilities
405
384
-615
469
Net cash used in operating activities
-54,109
-51,112
-44,865
-62,119
Purchases of property and equipment
0
-
1
-1
Purchases of investments
471,326
50,899
33,996
58,076
Proceeds from maturities and sales of investments
118,300
83,800
69,460
97,800
Net cash (used in) provided by investing activities
-353,026
32,901
35,463
39,725
Proceeds from issuance of common stock via at-the-market offerings, net
22,129
137,090
-
-
Proceeds from issuance of common stock through follow-on offering, net
296,814
-
-
-
Proceeds from issuance of common stock through exercise of stock options
3,891
1,692
507
17
Proceeds from issuance of common stock via employee stock purchase plan
901
-
427
0
Net cash provided by financing activities
323,735
138,782
934
17
Net increase (decrease) in cash, cash equivalents, and restricted cash
-83,400
120,571
-8,468
-22,377
Cash, cash equivalents and restricted cash at beginning of period
205,925
85,354
93,822
126,406
Cash, cash equivalents and restricted cash at end of period
122,525
-
-
-
Periodic change in additions of property and equipment within current liabilities
0
-
-
-
Periodic change in costs to obtain license agreement within current liabilities
0
-
-
-
Operating lease assets obtained in exchange for operating lease liabilities
0
-
-
-
Cash and cash equivalents
121,189
-
-
-
Restricted cash
1,336
-
-
-
Cash, cash equivalents, and restricted cash per statements of cash flows
122,525
205,925
85,354
93,822
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock through...
$296,814K
Proceeds from issuance of
common stock via...
$22,129K
Proceeds from issuance of
common stock through...
$3,891K
Proceeds from issuance of
common stock via...
$901K
(37.98%↑ Y/Y)
Net cash provided by
financing activities
$323,735K
(49476.57%↑ Y/Y)
Net increase
(decrease) in cash, cash...
-$83,400K
(-717.09%↓ Y/Y)
Canceled cashflow
$323,735K
Proceeds from maturities
and sales of...
$118,300K
(-20.56%↓ Y/Y)
Accounts payable and
accrued expenses
$20,522K
(566.52%↑ Y/Y)
Stock compensation
expense
$9,179K
(-72.86%↓ Y/Y)
Operating lease assets and
liabilities, net
-$507K
(-109.59%↓ Y/Y)
Other liabilities
$405K
(129.33%↑ Y/Y)
Depreciation expense
$360K
(-83.71%↓ Y/Y)
Net cash (used in)
provided by investing...
-$353,026K
(-400.16%↓ Y/Y)
Canceled cashflow
$118,300K
Net cash used in
operating activities
-$54,109K
(57.88%↑ Y/Y)
Canceled cashflow
$30,973K
Purchases of investments
$471,326K
(1425.38%↑ Y/Y)
Net loss
-$83,707K
(43.23%↑ Y/Y)
Prepaid expenses and
other current assets
$751K
(142.77%↑ Y/Y)
Net amortization of
premiums and discounts on...
$624K
(-79.14%↓ Y/Y)
Buy us a coffee